94193-38-1

Basic information

• Product Name: N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide
• Synonyms: N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide
• CAS NO: 94193-38-1
• Molecular Weight: 348.399
• Mol File: 94193-38-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide(94193-38-1)
• EPA Substance Registry System: N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide(94193-38-1)

Safety Data

• Hazardous Substances Data: 94193-38-1(Hazardous Substances Data)

Upstream product

• 100-60-7 N-methylcyclohexylamine 
• 94193-37-0 4-(3-Formyl-4-nitro-phenoxy)-butyryl chloride 
• 94193-36-9 4-(3-formyl-4-nitrophenyl)oxybutanoic acid 
• 94193-35-8 ethyl 4-((3-formyl-4-nitrophenyl)oxy)butyrate 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 

Downstream Products

• 116005-81-3 N-cyclohexyl-N-methyl-4-[2-amino-3-(carbamoylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 114703-76-3 N-Cyclohexyl-N-methyl-4-[2-amino-3-(ethoxycarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide Hydrobromide 
• 114703-84-3 N-cyclohexyl-N-methyl-4-[2-amino-3-(isopropoxycarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 114703-83-2 N-cyclohexyl-N-methyl-4-[2-amino-3-(cyclohexyloxycarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 114703-87-6 N-cyclohexyl-N-methyl-4-[2-amino-3-(4-morpholinylcarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 116005-80-2 4-(2-Amino-3-phenylcarbamoylmethyl-3,4-dihydro-quinazolin-6-yloxy)-N-cyclohexyl-N-methyl-butyramide; hydrobromide 
• 114703-82-1 N-cyclohexyl-N-methyl-4-<<2-amino-3-<(tert-butyloxycarbonyl)methyl>-3,4-dihydroquinazolin-6-yl>oxy>butyramide hydrobromide 
• 116005-79-9 N-cyclohexyl-N-methyl-4-[2-amino-3-(1-piperidinylcarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 116005-78-8 {2-Amino-6-[3-(cyclohexyl-methyl-carbamoyl)-propoxy]-4H-quinazolin-3-yl}-acetic acid 2,2-dimethyl-propyl ester; hydrobromide 
• 114703-86-5 {2-Amino-6-[3-(cyclohexyl-methyl-carbamoyl)-propoxy]-4H-quinazolin-3-yl}-acetic acid 1,2,2-trimethyl-propyl ester; hydrobromide 
• 114703-85-4 {2-Amino-6-[3-(cyclohexyl-methyl-carbamoyl)-propoxy]-4H-quinazolin-3-yl}-acetic acid 1-phenyl-ethyl ester; hydrobromide 
• 105763-67-5 {5-[3-(Cyclohexyl-methyl-carbamoyl)-propoxy]-2-nitro-benzylamino}-acetic acid ethyl ester 
• 68550-75-4 cilostamide 
• 69592-33-2 N-Cyclohexyl-N-methyl-4-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yloxy)-butyramide 

Relevant articles and documents

1H-1,2,4-thiadiazolo(3,4-b)quinazolin-5-one-2,2-dioxides, and a method for increasing the cardiac output of a mammal with them

1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxides are disclosed. These compounds are useful as caridotonic agents. A preferred compound is 7-(n-cyclohexyl-N-methyl-4-amino-4-oxobutyloxy)-1H-1,2,4-thiadiazolo[3,4-b]quinazolin-5-one-2,2-dioxide.

Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides

Compounds according to the formula STR1 and the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer of 1 to 6; R1 is hydrogen or alkyl of 1 to 4 carbon; R2 is hydrogen or R1 and R2 combined are oxo; R3 is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its acylates, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or amino acid side chains; R4 is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl; Y is hydrogen, alkyl of 1 to 4 carbon atoms, halo or lower alkoxy; A is an amide forming group wherein the nitrogen substituents are: hydrogen; alkyl of 1 to 6 carbon atoms; hydroxyalkyl of 1 to 6 carbon atoms and its aliphatic acylates of 1 to 6 carbon atoms or aryl acylates of 7 to 12 carbon atoms; cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a lower alkyl, lower alkoxy, --OH, --OCOR5, halo, --NH2, --N(R5)2, --NHCOR5, --COOH, or --COO(R5) group wherein R5 is lower alkyl; phenyl or phenyl lower alkyl wherein phenyl is unsubstituted or substituted with 1 or more lower alkyl, halo or lower alkoxy groups or an --NH2, --N(R5)2, --NHCOR5, --COOH, or --COOR5 group wherein R5 is lower alkyl; morpholinyl; piperidinyl; perhexylenyl; N-loweralkylpiperazinyl; pyrrolidinyl; tetrahydroquinolinyl; tetrahydroisoquinolinyl; (±)-decahydroquinolinyl or indolinyl. These compounds have inotropic activity.